文献速递浆细胞疾病

是否应修订骨髓瘤诊断标准?血清游离轻链比值≥100的十年证据

Time to revise myeloma diagnostic criteria? A decade of accumulated evidence on a serum free light chain ratio of ≥100.
PubMed 文献 · Blood · 2026-01-01

2014年IMWG将血清游离轻链比值≥100作为独立骨髓瘤定义事件,但后续数据显示该组2年进展风险低至30.4%。约70%以上患者24小时单克隆蛋白尿<200 mg,该亚组2年进展风险仅13.5%,作者建议立即修订诊断标准。

要点

  • sFLC比值≥100作为独立骨髓瘤定义事件的进展风险被高估,2年进展率可低至30.4%。
  • sFLC比值≥100且24小时单克隆蛋白尿<200 mg者2年进展风险仅13.5%,肾功能衰竭风险极低。
  • 建议将sFLC比值≥100从骨髓瘤定义事件中移除,并纳入高危冒烟型骨髓瘤的前瞻性研究。

核心结论

  • 作者提出应立即修订诊断标准,移除sFLC比值≥100作为独立骨髓瘤定义事件。
  • 建议将sFLC比值≥100的患者排除在新诊断骨髓瘤试验之外,并纳入高危SMM的前瞻性研究及现代影像学主动监测。

研究设计与样本

  • 本文为基于文献与登记数据的综述性分析,未报告系统检索范围。

主要发现

  • 基于人群的登记数据显示,sFLC比值≥100组2年进展风险低至30.4%。
  • 后续数据显示超过70%的sFLC比值≥100患者24小时单克隆蛋白尿<200 mg。
  • 24小时单克隆蛋白尿<200 mg亚组2年进展风险为13.5%,且不可逆肾功能衰竭风险极低。

关键数值与推荐

  • 2014年IMWG将sFLC比值≥100作为独立骨髓瘤定义生物标志物,依据是2年进展风险约80%。
  • 当前高危SMM早期干预试验将sFLC比值≥100纳入无进展生存复合终点,可能将生化变化误判为临床事件。

临床怎么用

  • 对sFLC比值≥100患者应评估24小时单克隆蛋白尿,蛋白尿<200 mg者进展风险低,可考虑主动监测。
  • 在高危SMM试验中应避免将sFLC比值≥100单独作为进展事件,需结合现代影像学定义自然史。

局限性

  • 本文为观点性综述,未报告系统检索策略与纳入研究的方法学质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2014, the International Myeloma Working Group (IMWG) expanded multiple myeloma diagnostic criteria to include a serum free light chain (sFLC) ratio of ≥100 as a standalone myeloma-defining biomarker, based on studies suggesting ∼80% risk of progression to overt myeloma at 2 years. However, subsequent studies demonstrate a substantially lower risk of progression, with population-based registry data showing a 2-year risk as low as 30.4% in this group. Importantly, subsequent data showed that >70% of patients with an sFLC ratio ≥100 have 24-hour monoclonal proteinuria <200 mg, a subgroup with particularly low progression risk (13.5% at 2 years) and minimal risk of irreversible renal failure. Furthermore, with the IMWG diagnostic amendment, an sFLC ratio ≥100 is currently included within the composite end point of progression-free survival in early-intervention clinical trials of high-risk smoldering multiple myeloma (SMM), which poses a risk of misclassifying biochemical changes as clinically meaningful events. We propose immediate revision of the diagnostic criteria to remove sFLC ratio ≥100 as a standalone myeloma-defining event and exclusion of patients with an sFLC ratio ≥100 from trials of newly diagnosed myeloma. These patients should be included in prospective studies on therapeutic interventions in high-risk SMM as well as active surveillance with modern imaging to define their natural history in the contemporary era.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chakraborty R, Mohyuddin GR. Time to revise myeloma diagnostic criteria? A decade of accumulated evidence on a serum free light chain ratio of ≥100. Blood. 2026. PMID: 41557896. doi:10.1182/blood.2025031907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。